-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Names & News
-
Shirish Gadgeel, MD
Posted: June 24, 2020 Shirish Gadgeel, MD, is now the Chief of Division of Hematology and Oncology and Associate Director of Patient Experience and Clinical Care at Henry Ford Cancer Institute/Henry Ford Hospital, Detroit, Michigan. He is also a Professor at Wayne State University, where he previously served as leader of the Thoracic Oncology Multidisciplinary…
-
Karen L. Reckamp, MD, MS
Posted: June 24, 2020 In addition to her roles of Associate Director for Clinical Research at Cedars-Sinai Cancer and Medical Oncology Director of Women’s Guild Lung Institute in the Department of Medicine at Cedars-Sinai Cancer, Karen L. Reckamp, MD, MS, has been named the Director of the Division of Medical Oncology there. Most recently, Dr.…
-
Gideon Blumenthal, MD
Posted: June 24, 2020 Gideon Blumenthal, MD, has transitioned from Deputy Director of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA) to Vice President of Global Regulatory Affairs for Oncology at Merck. Dr. Blumenthal was with the FDA for more than a decade, after more than 12 years of…
-
David LeDuc
Posted: June 24, 2020 David LeDuc has been named Associate Director, Oncology Patient Affairs at Astra-Zeneca. In this role, Mr. LeDuc will be responsible for building and strengthening relationships with key stakeholders and advocates and incorporating the patient voice in all aspects of the company’s work. Mr. LeDuc came to AstraZeneca from the Go2 Foundation…
-
Gustave Roussy’s New Leadership
Posted: April 16, 2020 Professor Jean-Charles Soria has been appointed general director of Gustave Roussy for a term of 5 years. A medical oncologist and professor of medicine at Paris-Saclay University, Prof. Soria was the director of the Gustave-Roussy SIRIC Socrate (Integrated Cancer Research Site) between 2012 and 2017. Since September 2017, Prof. Soria was…
-
Fred Hutchinson’s New President, Director
Posted: April 16, 2020 Dr. Thomas J. Lynch Jr. has been named the new president and director of the Fred Hutchinson Cancer Research Center. Most recently Dr. Lynch was chief scientific officer at Bristol- Myers Squibb, where he oversaw research and development for oncology, cardiovascular disease, fibrosis, and immunoscience. Previously chairman and CEO of Massachusetts…
-
Dr. Chandra P. Belani Named New Chief Science Officer for the IASLC
Posted: February 12, 2020 December 2, 2019—The International Association for the Study of Lung Cancer named Chandra P. Belani, MD, as its new chief science officer (CSO). As CSO, Dr. Belani will direct, guide, and support the IASLC scientific strategy, including, but not limited to, scientific research projects, publications, educational content for conferences, and educational…
-
Jeffrey Bradley, MD, FASTRO
Posted: December 11, 2019 Jeffrey Bradley, MD, FASTRO, is the new executive vice chairman of the Department of Radiation Oncology at Winship Cancer Institute of Emory University. Previously Dr. Bradley was the S. Lee Kling Endowed Professor of Radiation Oncology, clinical director of the Kling Proton Center, and chief of the Radiation Oncology Thoracic Cancer…
-
Vassiliki Papadimitrakopoulou, MD
Posted: December 11, 2019 Vassiliki Papadimitrakopoulou, MD, has left The University of Texas MD Anderson Cancer Center, where she was a professor of medicine in the Department of Thoracic/Head and Neck Medical Oncology, to join Pfizer Oncology as the Clinical Development Leader. Dr. Papadimitrakopoulou is also a member of the FDA’s Oncologic Drugs Advisory Committee…
-
Stephen M. Hahn, MD, FASTRO
Posted: December 11, 2019 Stephen M. Hahn, MD, FASTRO, has been nominated to be the next commissioner of the U.S. Food and Drug Administration by President Trump. If approved by the Senate, Dr. Hahn will vacate his position as chief executive officer of The University of Texas MD Anderson Cancer Center, which he has held…